Bausch + Lomb Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
The controlling position of Bausch Health, not any dispersed public base, defines Bausch + Lomb's ownership and dominates its investment case. Bausch Health Companies holds about 87.7 percent of the shares, leaving public investors, with Vanguard and BlackRock among the largest, owning only the roughly 12.3 percent minority. That control is the product of a partial separation that was never completed: Bausch Health listed a minority interest in Bausch + Lomb through a May 2022 initial public offering intending eventually to spin off the rest, but the full separation has stalled, complicated by the parent's substantial debt and by legal and financial considerations, and a 2024 strategic review that explored selling Bausch + Lomb ended in 2025 without a transaction. What public shareholders own, then, is a minority stake in a strong eye-health business whose strategic destiny is controlled by a heavily indebted parent. The underlying franchise, a global leader across contact lenses, surgical products, eye pharmaceuticals and consumer eye care, is genuinely attractive, but its minority holders cannot direct its future and remain exposed to Bausch Health's balance-sheet pressures and separation decisions. The equity's value therefore hinges not only on the eye-health business's performance but on the unresolved question of whether and how Bausch Health ultimately separates or monetizes its majority stake, an overhang that shapes the stock as much as the operations do.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Roughly 5.1 billion dollars of revenue flows through Bausch + Lomb, which operates an attractive, diversified eye-health business, but its public shareholders own only a minority stake overshadowed by the control and unresolved intentions of its parent. The underlying appeal is real: Bausch + Lomb is a global leader in eye health with strong positions across contact lenses and lens care through brands like Biotrue, ULTRA and INFUSE, surgical products including intraocular lenses, prescription eye pharmaceuticals such as the dry-eye treatments MIEBO and XIIDRA, and consumer eye-health brands like LUMIFY and PreserVision, all benefiting from durable demand driven by aging populations and rising eye-care needs. Against this stands the dominant risk: Bausch Health's roughly 87.7 percent control, its substantial debt, and the stalled separation that a 2024 sale process failed to resolve, leaving public holders unable to influence the company's strategic direction and exposed to the parent's financial pressures and eventual decisions about its stake. The uncertainty over whether Bausch Health will spin off, sell or retain its majority interest creates a persistent overhang. The equity offers exposure to a strong eye-health franchise at a discount reflecting that control overhang, and its returns depend not only on the business's operating performance and the success of products like MIEBO and XIIDRA but on the resolution of the parent's majority stake, making the ownership situation, as much as the operations, the decisive factor for minority shareholders.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Bausch + Lomb | Brand | Global eye-health franchise |
| Biotrue | Brand | Contact lenses and lens care |
| ULTRA | Brand | Silicone hydrogel contact lenses |
| INFUSE | Brand | Daily disposable contact lenses |
| LUMIFY | Brand | Redness-relief eye drops |
| Ocuvite | Brand | Eye-health supplements |
| PreserVision | Brand | Age-related eye-health supplements |
| MIEBO | Brand | Prescription dry-eye treatment |
| XIIDRA | Brand | Prescription dry-eye treatment |
| enVista | Brand | Intraocular lenses |
Portfolio Analysis
Bausch + Lomb's competitive strength rests on one of the most trusted brands in eye health and a broad portfolio spanning the entire field of vision care. The flagship Bausch + Lomb name carries more than a century and a half of recognition among eye-care professionals and consumers, anchoring a diversified portfolio: in vision care, contact-lens and lens-care brands like Biotrue, ULTRA and INFUSE compete in the large global lens market; in surgery, intraocular lenses such as enVista serve cataract and refractive procedures; in pharmaceuticals, prescription treatments including the dry-eye therapies MIEBO and XIIDRA address chronic eye conditions; and in consumer health, LUMIFY redness-relief drops and the Ocuvite and PreserVision eye-health supplements reach retail shelves. The strategy is to be a comprehensive, integrated eye-health company spanning devices, pharmaceuticals and consumer products, leveraging the strength and breadth of the Bausch + Lomb brand and its relationships with eye-care professionals across the full continuum of vision care. Its competitive strength lies in that trusted brand, the breadth of its portfolio across contact lenses, surgery, pharmaceuticals and consumer products, and the durable demand for eye care driven by aging populations. Its competitive identity is that of a venerable, comprehensive eye-health company, and the durability of that identity depends on continued innovation in contact lenses, surgical products and pharmaceuticals, and on the strength of its brand holding up against focused competitors, even as the overhang of majority ownership complicates its strategic freedom.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Bausch + Lomb ★ | N/A | $5.101B FY2025 | Integrated global eye-health company |
| Alcon | N/A | $10B FY2025 | Eye-care devices and vision products leader |
| CooperCompanies | N/A | $4B FY2025 | Contact-lens and women's-health company |
| Johnson and Johnson Vision | N/A | N/A | Contact-lens and surgical-vision business |
| AbbVie | N/A | $56B FY2025 | Pharmaceutical company with eye-care products |
Competitive Analysis
Bausch + Lomb competes across the full breadth of eye health against focused and formidable rivals, and it does so while carrying the strategic constraint of majority ownership by its parent. Its principal competitors are the eye-care leader Alcon in devices and vision products, CooperCompanies in contact lenses, Johnson and Johnson Vision in contact lenses and surgical vision, and AbbVie in eye pharmaceuticals, all strong in their respective areas. Bausch + Lomb's competitive footing rests on the trust and recognition of its venerable brand, the breadth of its integrated portfolio spanning contact lenses, surgery, pharmaceuticals and consumer eye health, its relationships with eye-care professionals, and the durable demand for eye care driven by aging populations and rising vision needs. The pressures it faces are considerable: strong, focused competitors in each of its markets, the need for continuous innovation in contact lenses and surgical and pharmaceutical products, and, distinctively, the strategic overhang of majority control by a heavily indebted parent whose separation intentions remain unresolved, which can constrain the company's flexibility and cloud its strategic direction. Bausch + Lomb competes as a comprehensive, well-branded eye-health company against sharper single-focus rivals, and its competitive prospects depend on sustaining innovation and brand strength across its diversified portfolio while navigating the constraints that its parent's control imposes, a competitive position grounded in breadth and brand but complicated by an ownership structure that its rivals do not share.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| XIIDRA | $1.75B upfront | 2023 | Added a leading prescription dry-eye treatment |
| Trukera Surgical | $196M | 2023 | Expanded surgical diagnostics and consumables |
| Blink product line | $107M | 2023 | Expanded over-the-counter eye drops |
| Bausch + Lomb | IPO | 2022 | Bausch Health sold a minority interest to public investors |
Acquisitions Analysis
Bausch + Lomb's corporate history has been shaped by ownership changes and acquisitions, and its recent dealmaking has strengthened its eye pharmaceuticals and surgery businesses even as its own separation remains unresolved. The company itself passed through private-equity and pharmaceutical ownership, taken private by Warburg Pincus in 2007 and acquired by Valeant, later Bausch Health, in 2013. Since Bausch Health listed a minority interest in 2022, Bausch + Lomb has made targeted acquisitions to broaden its portfolio: the 2023 acquisition of XIIDRA rights for 1.75 billion dollars upfront added a leading prescription dry-eye treatment, complementing its own MIEBO, while the purchases of Trukera Surgical for 196 million and the Blink over-the-counter eye-drop line for 107 million that same year expanded its surgical and consumer offerings. These deals have deepened the company's positions in the growing dry-eye and surgical markets. The defining unresolved corporate question, however, is not an acquisition but the incomplete separation from Bausch Health and the 2024 sale process that ended without a transaction. Value creation therefore depends both on the eye-health business's acquisitions and organic innovation and on the resolution of the parent's majority stake, and while Bausch + Lomb has used acquisitions to strengthen its eye-care franchise, its future is bound up as much with Bausch Health's decisions about its 87.7 percent interest as with the company's own dealmaking.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Bausch + Lomb's corporate structure reflects a history of ownership changes culminating in an incomplete separation from its parent. Founded in 1853 and long an independent public company, Bausch + Lomb was taken private by Warburg Pincus in 2007 and then acquired in 2013 by Valeant Pharmaceuticals, which later became Bausch Health Companies, folding the eye-health business into a larger, heavily indebted pharmaceutical group. Bausch Health sought to unlock value by separating Bausch + Lomb, listing a minority interest through a May 2022 initial public offering while retaining control, with the intention of a subsequent full spinoff. That separation has stalled: the planned full spinoff remains incomplete, complicated by the parent's debt and by legal and financial considerations, and a 2024 strategic review that explored selling Bausch + Lomb ended in 2025 without a transaction, leaving Bausch Health with about 87.7 percent of the shares and public investors a minority. The resulting structure is a publicly listed eye-health company that remains majority-controlled by a parent whose separation intentions are unresolved. That structural limbo, a partially separated subsidiary awaiting a full separation that has not come, is the defining structural feature of Bausch + Lomb, and its ultimate structure depends entirely on whether and how Bausch Health completes the spinoff, sells its stake, or retains control, an unresolved question that overhangs the company.
Ownership History
Ownership History Analysis
Bausch + Lomb's history is among the longest in eye health, running from a nineteenth-century optical shop to a globally recognized eye-care company, though its recent chapters have been defined by ownership. John Bausch and Henry Lomb founded the company in 1853, and over more than a century and a half it became a leader in contact lenses, surgical products, eye pharmaceuticals and consumer eye care. Its modern history turned on ownership changes: Warburg Pincus took it private in 2007, and Valeant, later Bausch Health, acquired it in 2013, folding the eye-health business into a large, debt-laden pharmaceutical group. Seeking to unlock its value, Bausch Health listed a minority interest through a 2022 initial public offering intending a full separation, but that spinoff has stalled, and a 2024 process to sell the company ended without a deal, leaving Bausch Health with about 87.7 percent control. Generating about 5.1 billion dollars of revenue with roughly 13,000 employees, Bausch + Lomb is a strong eye-health franchise awaiting resolution of its ownership. Its history is that of a venerable eye-care company that built enduring brands and broad market positions, passed through private-equity and pharmaceutical ownership, and now exists as a majority-controlled subsidiary whose independence, long intended, remains unrealized, its future bound up with its parent's decisions about a separation that has yet to be completed.
Ownership Explained
Bausch + Lomb is one of the world's oldest and best-known eye-health companies, a Vaughan, Ontario business founded in 1853 and listed on the New York and Toronto exchanges as BLCO, though it remains majority-controlled by its parent, Bausch Health Companies, which holds about 87.7 percent of the shares. Public investors own the roughly 12.3 percent minority, with Vanguard and BlackRock among the largest outside holders. Roughly 13,000 employees generated about 5.1 billion dollars of revenue in 2025 across contact lenses and lens care, surgical products, prescription eye pharmaceuticals and consumer eye-health brands, including Biotrue, ULTRA, LUMIFY, PreserVision, MIEBO and XIIDRA. A planned full separation from Bausch Health has remained incomplete after a 2024 sale process ended without a transaction.
A Bausch + Lomb share is a minority claim on a strong eye-health franchise that sits under the control of a heavily indebted parent, and that control is the defining feature of the investment. Bausch Health owns about 87.7 percent of the company and has long intended to separate it fully, but the planned spinoff has stalled and a 2024 process to sell Bausch + Lomb ended without a deal, leaving public holders as a minority whose fortunes are entangled with the parent's balance sheet and strategic decisions. The underlying business, a global leader in contact lenses, surgical products, eye pharmaceuticals and consumer eye care, is attractive, but its public shareholders bear the overhang of majority control by a parent whose debt and intentions shape the stock.